Hims & Hers Stocks Plunge 15.37% as Margin Squeeze Forces EBITDA Guidance Cut

What happened

Hims & Hers Health reported third-quarter revenue of $890.4 million, up 49%, but said gross margin fell to 57% from 74% and it recorded a $33.0 million net loss. The company lowered its full-year adjusted EBITDA outlook to $257 million-$277 million for 2026.

Confirmed

Global impact / market context

The results show that faster sales did not translate into stronger profit: gross margin fell as subscriber growth lagged revenue growth. Lower profit expectations can weaken confidence in the growth outlook, while the planned marketing slowdown and platform expansion may affect customer acquisition costs and future revenue.

Analyst inference

The article describes a company whose revenue is growing quickly but whose profit per sale is under pressure. Fourth-quarter revenue guidance implies a slight dip at the midpoint, and adjusted EBITDA margin is down from a year ago, making renewed subscriber growth without further margin damage central to the outlook.

Analyst inference

What to watch

1. Check whether fourth-quarter platform expansions lift subscriber growth; the article says the company plans these expansions and needs them to restart growth. Analyst inference
2. Compare fourth-quarter revenue with the $875 million-$895 million guidance range and assess whether the midpoint dip is followed by renewed growth. Confirmed
3. Watch gross margin and adjusted EBITDA margin, which means adjusted operating earnings as a share of revenue, for signs that expansion and marketing costs are easing. Analyst inference

Evidence

• gurufocus.com